Sermorelin & GHRP-2 & GHRP-6 vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Sermorelin & GHRP-2 & GHRP-6
A powerful tri-blend combining Sermorelin (a GHRH analog) with two growth hormone releasing peptides. This combination produces significantly greater GH release than any single peptide, with studies showing up to 54-fold increases in pulsatile GH secretion.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | Sermorelin & GHRP-2 & GHRP-6 | Cagrilintide |
|---|---|---|
| Mechanism | Sermorelin stimulates the pituitary via GHRH receptors, while GHRP-2 and GHRP-6 act as ghrelin mimetics on different receptor subtypes. The combination creates synergistic GH release through multiple complementary pathways. GHRP-6 also strongly stimulates appetite. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Typical protocols: Sermorelin 100-300mcg, GHRP-2 100-300mcg, GHRP-6 100-300mcg. Often administered 2-3 times daily, 30 minutes before meals or at bedtime. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | Subcutaneous injection. Best administered fasted or before sleep to maximize natural GH cycle. The three peptides can be mixed together or administered separately. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | Increased hunger (especially from GHRP-6), water retention, facial flushing, nausea, tingling, potential increases in cortisol and prolactin levels. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |
What They Have in Common
Both Sermorelin & GHRP-2 & GHRP-6 and Cagrilintide are commonly used for: